Consumers don’t always pay more because they’re uninformed. Sometimes they pay more because the market quietly trains them to trust.
That’s the uncomfortable truth behind “branded generics”—a category that sits at the intersection of patent strategy, b…
Why Consumers Pay a “Trust Premium” for Branded Generics Read Post »
AI is starting to “know” your drug the way investors do—before you do.
If you’re in pharma, you’ve felt the shift: competitive intelligence used to be a slow, manual grind—patent searches, label reviews, pipeline scans, conference chatter. Now, AI to…
What AI Knows About Your Drug vs. Your Competitors Read Post »
Most pharma teams don’t lose because they lack data. They lose because they don’t close the loop.
Here’s the uncomfortable truth: the “intelligence gap” isn’t about having fewer signals—it’s about failing to operationalize them. In patent strategy, tha…
Read the Patent, Beat the Competition: The Intelligence Gap Most Pharma Teams Leave Open Read Post »
Two systems. One fight. How the “patent dance” and Orange Book linkage are quietly shaping a $400B biologics war.
In the U.S. biologics market, the real contest isn’t just between molecules—it’s between timelines. Between procedural leverage. Between t…
Most teams don’t lose to competitors because they’re less talented—they lose because they’re late.
In pharma, “late” can mean a competitor launches first, pricing pressure hits sooner than expected, and your pipeline suddenly has to defend against a wa…
Find Expired Drug Patents Before Your Competitors Do Read Post »
The patent cliff isn’t a cliff anymore—it’s a battlefield.
For years, the story around “patent expiration” has been told as a simple timeline: exclusivity ends, generic entry follows, revenues fall. But the modern playbook is more tactical—and it’s bei…
AI is becoming the new KOL in pharma—and most teams aren’t tracking it.
Here’s the uncomfortable truth: the “opinion leader” isn’t always a person anymore. It’s a model.
In drug development, we’ve spent years mapping influence—key opinion leaders, advi…
AI Is Your Drug’s New KOL — and You’re Not Tracking It Read Post »
Most companies don’t miss the patent—they miss the money.
Drug patent expiry is treated like a countdown clock: watch the date, model the revenue impact, plan the next product. But in practice, the biggest value often isn’t lost on the day the patent…
Drug patent expiry isn’t a calendar event—it’s a portfolio risk model. Here’s how to forecast it by country.
Most pharma teams treat patent expiry like a single date on a single spreadsheet. That’s how you end up surprised by launch timelines, pricing …
Generic entry is inevitable—unless you build a moat that doesn’t show up on a balance sheet.
Most investors and operators obsess over composition-of-matter patents: the headline-grabbing, courtroom-ready IP that blocks competitors from making the drug …
Get new actionable insights and updates from BiotechBlog
